best cheap cryptocurrency to buy 2021 Top Related searches

Zhejiang Securities Regulatory Bureau: issued a warning letter to Hangzhou Huayu Frequent Private Equity Fund Co., Ltd. On December 13, the website of Zhejiang Securities Regulatory Bureau issued a decision on taking measures to issue a warning letter to Hangzhou Huayu Frequent Private Equity Fund Co., Ltd. After investigation, the company has the following behaviors in carrying out private equity fund business: 1. There are irregularities in the appropriate materials of fund products managed by investors, and the company has not made further audit; Second, the risk control review process of related party transactions is not perfect. The above behavior violates the first paragraph of Article 4 of the Interim Measures for the Supervision and Administration of Private Investment Funds (Order No.105 of the CSRC). According to the provisions of Article 33 of the Interim Measures for the Supervision and Administration of Private Investment Funds, Zhejiang Securities Regulatory Bureau decided to issue a warning letter to the company and record it in the integrity file of the securities and futures market.Zhengrong Real Estate and others were forced to execute 230 million yuan. According to the information of legal proceedings, recently, Zhengrong Real Estate Holdings Co., Ltd. and Minhou Zhenghong Real Estate Development Co., Ltd. added a piece of information about the person to be executed, with an execution target of more than 230 million yuan. The enforcement court is Fuzhou Intermediate People's Court of Fujian Province.HKEx: HSBC repurchased 527,200 shares for HK$ 39.4 million on December 12.

Alipay sells cryptocurrency funds? Originally an indirect investment in a product of Huabao Fund, the subscription has been suspended. Recently, some netizens found that Huabao Fund promoted a fund product issued by Huabao Fund in Alipay-QDII-FOF-LOF C (hereinafter referred to as "Huabao Overseas Technology C"), promoting "riding the wind to encrypt the rising market of currency" and "the representative of subversive innovation technology: cryptocurrency". According to the report of Warburg Overseas Technology C in the third quarter of this year, among the top ten funds with the highest fair value at the end of the reporting period, five were only index funds managed by Ark Investment Management under Cathy Wood, the "Mujie", accounting for 73.12% of the total. Looking through the archives of ARK Management Fund, the reporter found that ARK Innvonation ETF (hereinafter referred to as "ARKK"), the largest heavyweight of Huabao Overseas Technology C, was invested in Coinbase, a cryptocurrency exchange. ARK Next Generation Internet ETF (hereinafter referred to as "ARKW"), the second largest warehouse, invests in GBTC(Grayscale Bitcoin Trust) or investment tools such as Bitcoin, Ethereum and other cryptocurrency ETFs. ARKW also suggests the risks related to the indirect investment of funds in cryptocurrencies. In addition, Coinbase ranks third among ARKW's heavy stocks. The reporter logged on to several consignment platforms such as Ant Fortune, Licaitong, Tiantian Fund, China Merchants Bank, Snowball Fund and found that the product was sold on the above platforms, but from December 11th, the large subscription of Class A shares and Class C shares was suspended, and the daily limit for each person was 1000 yuan RMB. However, on December 13th, Huabao Overseas Science and Technology Stock Securities Investment Fund announced that it would suspend subscription and regular fixed investment business. (21 Finance)Guangdong: In the next five years, 10 billion yuan will be invested to support the development of the tourism industry. On December 12th, a site meeting was held to promote the implementation of the spirit of the provincial tourism development conference in Guangdong. The meeting proposed to promote the implementation of the "three hundred" plan for cultural tourism investment, that is, to promote 100 major projects under construction and 100 key investment projects, to coordinate provincial financial investment of 10 billion yuan to support the development of tourism industry in the next five years, and to accelerate the implementation of the list of 100 major projects under construction and 100 key investment projects. According to the deployment, Guangdong will focus on promoting the implementation of the "three hundred" plan for cultural tourism investment and establishing "three lists" for key cultural tourism projects (namely, the list of projects under construction, the list of investment projects and the list of projects supported by financial funds). According to statistics, there are 103 major cultural tourism projects under construction in Guangdong province, with a total investment of 282.6 billion yuan, and the accumulated investment has reached 74 billion yuan by the third quarter.Borui Medicine: Carboprost injection is planned to win the bid for the national centralized drug procurement. Borui Medicine announced that in the tenth batch of national centralized drug procurement in which Borui Pharmaceutical, a wholly-owned subsidiary, participated, carboprost tromethamine injection is planned to win the bid. This product is mainly used for 13-20 weeks pregnant abortion and postpartum hemorrhage. The specification is 1 ml: 250μ g, and the proposed bid price is 16.96 yuan/piece. In the first year, the agreed purchase base is 220,400 pieces, which are mainly supplied to Henan, Hubei, Guangxi, Shaanxi, Gansu, Ningxia and other provinces. If the contract is finally selected and signed, it will help the product to quickly open the domestic market and enhance the market share and brand influence of the company. The product obtained the drug registration certificate in March 2024, and has not yet generated sales revenue.

The CSRC approved the registration application of Jiangnan New Materials Technology Co., Ltd. for initial public offering of shares. Yiling Pharmaceutical Co., Ltd.: The application for clinical trial of Lianhua Yuping Granule was approved, and Yiling Pharmaceutical announced that Beijing Yiling, a wholly-owned subsidiary, received the Notice of Approval for Clinical Trial of Drugs approved and issued by National Medical Products Administration on December 12, 2024, and agreed to carry out clinical trial of Lianhua Yuping Granule for qi deficiency syndrome of common cold.